#Sweden #Gothenburg #Board Elections #Annual General Meeting #Vitrolife AB

Overview of Vitrolife AB's Annual General Meeting

On April 29, 2025, Vitrolife AB convened its Annual General Meeting (AGM) in Gothenburg, Sweden, where significant resolutions shaping the future of the company were made. Here’s a detailed look at the highlights from the event.

Proposed Dividend Resolution

A noteworthy decision was made regarding the company's financial performance for the year 2024. The Board proposed a dividend of SEK 1.10 per share, which is a sign of the company's robust health and commitment to returning value to its shareholders. The record date for this dividend will be May 2, 2025, ensuring that all eligible shareholders receive their due payment.

Board Re-elections and Key Appointments

In a move to maintain continuity and confidence, the AGM saw the re-election of several key board members. Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson, and Karen Lykke Sørensen were all voted back into their positions, demonstrating strong support for the existing leadership. Following the re-elections, Jón Sigurdsson was appointed as Chairman of the Board, taking on a critical role in guiding the company’s strategic direction.

Board Member Compensation

The AGM also approved a remuneration package for the Board, amounting to a total of SEK 3,670,000, which reflects a rise from the previous year. Details of the compensation include SEK 1,350,000 for the Chairman, SEK 450,000 for each board member, a remuneration for the Chairman of the Audit Committee at SEK 160,000, and SEK 80,000 for other Audit Committee members. These figures highlight the company's commitment to rewarding its leadership team adequately while fostering accountability and governance.

Auditor Reappointment

Maintaining its relationship with seasoned auditing professionals, the AGM endorsed the re-election of Deloitte AB as the company’s auditor, adhering to unchanged remuneration principles. This decision ensures that the company continues to benefit from Deloitte’s expertise and oversight.

Share Issuance and Buyback Authorization

One of the critical resolutions involved granting the Board the authority to issue up to 13,544,719 new shares, amounting to nearly 10% of the company’s share capital. This move may potentially serve various purposes, including capital raising for future investments or strategic partnerships.

Additionally, the Board has been authorized to repurchase the company's own shares, a strategic move that could be beneficial for managing equity and enhancing shareholder value. The company will ensure its holdings do not exceed 10% of the total shares in circulation.

Executive Management Remuneration Guidelines

The AGM approved new guidelines for the remuneration and employment conditions of the executive management team, aligning compensation models with industry standards and company performance metrics.

Long-Term Incentive Plan

Finally, a resolution was passed to enter into a share swap agreement, intended to secure shares for participants in the Long-Term Incentive Plan (LTIP) 2025. This initiative underscores Vitrolife's commitment to long-term growth and aligning the interests of its management with those of shareholders, promoting a culture of performance and accountability.

Conclusion

The outcomes of Vitrolife AB's AGM reflect a proactive approach to governance and an unwavering focus on growth and shareholder value. By reappointing effective leadership and endorsing practical financial decisions, the company anticipates building a stronger foundation for future success. Stakeholders and investors are keen to see how these strategic decisions will unfold in the coming years, positioning Vitrolife as a resilient player in its industry.

For further inquiries or additional information regarding the AGM decisions, interested parties may contact Helena Wennerström, acting CFO, at +4670 822 80 86.